Dr. Nick Sharp, an entrepreneur, scientist, and veterinarian, is deeply committed to building companies at the intersection of science and medicine. As a clinician, he is double board-certified in veterinary surgery and neurology. His dedication to translational medicine goes back many years. He received his PhD from Duke University School of Medicine for identifying the mutation in a canine model for Duchenne muscular dystrophy, the first of just two large animal models now used to develop therapies for this disease. After spending over 20 years in academia, Nick has authored 135 scientific articles, including two books, 30 chapters, and 66 peer-reviewed publications. His current research interest is to analyze the clinical and market opportunities for RSK inhibition in oncology, particularly breast cancer. At present, he is one of just three directors who joined the board at the inception of PhoenixMD ten years ago. The chemistry efforts had only begun, and the first clinical lead had yet to be nominated. The company is now entering Phase 2 clinical trials with a first-in-class small molecule that can potentially change how we think about precision oncology in breast cancer and beyond.After his career in academia, in 2004, Nick became an owner and partner at Canada West Veterinary Specialists, where he helped to grow the business from a small team with a big vision to a 26,000 sq. ft., 24-hour emergency referral hospital. It is now one of North America's most successful, privately owned, multi-specialty veterinary practices.